November 24, 2017 2:37 PM ET

Biotechnology

Company Overview of Immunovative Therapies Ltd.

Key Executives for Immunovative Therapies Ltd.

NameBoard RelationshipsTitleAge
Michael Har-Noy No RelationshipsFounder and Chief Executive Officer--
Antonio Treminio 10 RelationshipsChairman of Immunovative Inc and Chief Executive Officer of Immunovative Inc47
Emmanuel Katsanis M.D.9 RelationshipsChairman of the Scientific Advisory Board, Chief Medical Officer and Medical Monitor--
Zivile Katiliene No RelationshipsDirector of Regulatory Affairs and Clinical Operations--

Immunovative Therapies Ltd. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Ronald W. Hart Ph.D. 54 RelationshipsZuma360 Software, Inc.75
Emmanuel Katsanis M.D. 9 RelationshipsImmunovative Therapies Ltd.--
Antonio Treminio 10 RelationshipsImmunovative Therapies Ltd.47
Malcolm R. Currie Ph.D. 88 RelationshipsGreystone Digital Technologies, Inc.89
Laurence Terrisse-Rulleau Ph.D. 38 RelationshipsCTI Life Sciences--
View All Board Members

Immunovative Therapies Ltd. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Advisory Board M.D.Emmanuel Katsanis9 Relationships7 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
389.1K
Bonus
242.6K
Total Short Term Compensation
486.4K
Total Value of Options
17.8M
Compensation as of Fiscal Year
Immunovative Therapies Ltd. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Joshua Brumm Resigns as Chief Operating Officer and Chief Financial Officer of Versartis, Inc
November 22, 2017 10:06 PM ET
dorsaVi Limited Appoints Caroline Elliott as Independent Non Executive Director and as the Chair of the Audit and Risk Committee, Effective November 24, 2017
November 22, 2017 9:49 PM ET
OncoCyte Corporation Announces Resignation of Don M. Bailey as Director
November 22, 2017 9:40 PM ET
BONESUPPORT HOLDING AB (publ) Announces Appointment of Nomination Committee
November 22, 2017 5:30 PM ET
Repligen Corporation Announces Retirement of Howard Benjamin as Vice President of Business Development and Executive Officer
November 22, 2017 12:36 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Immunovative Therapies Ltd., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.